IDEAS home Printed from https://ideas.repec.org/a/bla/biomet/v59y2003i3p487-496.html
   My bibliography  Save this article

Dose-Finding with Two Agents in Phase I Oncology Trials

Author

Listed:
  • Peter F. Thall
  • Randall E. Millikan
  • Peter Mueller
  • Sang-Joon Lee

Abstract

No abstract is available for this item.

Suggested Citation

  • Peter F. Thall & Randall E. Millikan & Peter Mueller & Sang-Joon Lee, 2003. "Dose-Finding with Two Agents in Phase I Oncology Trials," Biometrics, The International Biometric Society, vol. 59(3), pages 487-496, September.
  • Handle: RePEc:bla:biomet:v:59:y:2003:i:3:p:487-496
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1111/1541-0420.00058
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Silvio S. Zocchi & Anthony C. Atkinson, 1999. "Optimum Experimental Designs for Multinomial Logistic Models," Biometrics, The International Biometric Society, vol. 55(2), pages 437-444, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Nadine Houede & Peter F. Thall & Hoang Nguyen & Xavier Paoletti & Andrew Kramar, 2010. "Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials," Biometrics, The International Biometric Society, vol. 66(2), pages 532-540, June.
    2. Nolan A. Wages & Mark R. Conaway & John O'Quigley, 2011. "Continual Reassessment Method for Partial Ordering," Biometrics, The International Biometric Society, vol. 67(4), pages 1555-1563, December.
    3. B. Nebiyou Bekele & Yu Shen, 2005. "A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose-Finding Trial," Biometrics, The International Biometric Society, vol. 61(2), pages 343-354, June.
    4. Mauro Gasparini & Stuart Bailey & Beat Neuenschwander, 2010. "Bayesian dose finding in oncology for drug combinations by copula regression," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 59(3), pages 543-544, May.
    5. Guosheng Yin & Ying Yuan, 2009. "Bayesian dose finding in oncology for drug combinations by copula regression," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(2), pages 211-224, May.
    6. Thomas M. Braun & Shufang Wang, 2010. "A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents," Biometrics, The International Biometric Society, vol. 66(3), pages 805-812, September.
    7. Satoshi Morita & Peter F. Thall & Peter Müller, 2008. "Determining the Effective Sample Size of a Parametric Prior," Biometrics, The International Biometric Society, vol. 64(2), pages 595-602, June.
    8. Mark R. Conaway & Stephanie Dunbar & Shyamal D. Peddada, 2004. "Designs for Single- or Multiple-Agent Phase I Trials," Biometrics, The International Biometric Society, vol. 60(3), pages 661-669, September.
    9. Márcio A. Diniz & Sungjin Kim & Mourad Tighiouart, 2020. "A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades," Stats, MDPI, vol. 3(3), pages 1-18, July.
    10. Pavel Mozgunov & Rochelle Knight & Helen Barnett & Thomas Jaki, 2021. "Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study," IJERPH, MDPI, vol. 18(1), pages 1-19, January.
    11. Beibei Guo & Elizabeth Garrett‐Mayer & Suyu Liu, 2021. "A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 70(5), pages 1210-1229, November.
    12. Chunyan Cai & Ying Yuan & Yuan Ji, 2014. "A Bayesian dose finding design for oncology clinical trials of combinational biological agents," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 63(1), pages 159-173, January.
    13. Xuelin Huang & Swati Biswas & Yasuhiro Oki & Jean-Pierre Issa & Donald A. Berry, 2007. "A Parallel Phase I/II Clinical Trial Design for Combination Therapies," Biometrics, The International Biometric Society, vol. 63(2), pages 429-436, June.
    14. Kai Wang & Anastasia Ivanova, 2005. "Two-Dimensional Dose Finding in Discrete Dose Space," Biometrics, The International Biometric Society, vol. 61(1), pages 217-222, March.
    15. Beibei Guo & Suyu Liu, 2018. "Optimal Benchmark for Evaluating Drug-Combination Dose-Finding Clinical Trials," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 10(1), pages 184-201, April.
    16. Guosheng Yin & Ying Yuan, 2009. "A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents," Biometrics, The International Biometric Society, vol. 65(3), pages 866-875, September.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Idais, Osama, 2020. "Locally optimal designs for multivariate generalized linear models," Journal of Multivariate Analysis, Elsevier, vol. 180(C).
    2. Linda M. Haines & Inna Perevozskaya & William F. Rosenberger, 2003. "Bayesian Optimal Designs for Phase I Clinical Trials," Biometrics, The International Biometric Society, vol. 59(3), pages 591-600, September.
    3. Andreas Falke & Harald Hruschka, 2017. "Setting prices in mixed logit model designs," Marketing Letters, Springer, vol. 28(1), pages 139-154, March.
    4. Bodunwa, O. K. & Fasoranbaku, O. A., 2020. "D-optimal Design in Linear Model With Different Heteroscedasticity Structures," International Journal of Statistics and Probability, Canadian Center of Science and Education, vol. 9(2), pages 1-7, March.
    5. Guiteras, Raymond P. & Levine, David I. & Polley, Thomas H., 2016. "The pursuit of balance in sequential randomized trials," Development Engineering, Elsevier, vol. 1(C), pages 12-25.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:biomet:v:59:y:2003:i:3:p:487-496. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0006-341X .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.